Dean L. Schorno
2018 - Rigel Pharmaceuticals
In 2018, Dean L. Schorno earned a total compensation of $1.2M as Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $154,575 |
|---|---|
| Option Awards | $749,682 |
| Salary | $237,808 |
| Other | $52,096 |
| Total | $1,194,161 |
Schorno received $749.7K in option awards, accounting for 63% of the total pay in 2018.
Schorno also received $154.6K in non-equity incentive plan, $237.8K in salary and $52.1K in other compensation.
Rankings
In 2018, Dean L. Schorno's compensation ranked 8,314th out of 14,244 executives tracked by ExecPay. In other words, Schorno earned more than 41.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,314 out of 14,244 | 42nd |
Division Manufacturing | 3,293 out of 5,765 | 43rd |
Major group Chemicals And Allied Products | 1,236 out of 2,128 | 42nd |
Industry group Drugs | 1,032 out of 1,817 | 43rd |
Industry Pharmaceutical Preparations | 804 out of 1,391 | 42nd |
Source: SEC filing on April 9, 2019.
Schorno's colleagues
We found five more compensation records of executives who worked with Dean L. Schorno at Rigel Pharmaceuticals in 2018.
2018
Raul Rodriguez
Rigel Pharmaceuticals
Chief Executive Officer
2018
Dolly Vance
Rigel Pharmaceuticals
General Counsel
2018
Anne-Marie Duliege
Rigel Pharmaceuticals
Chief Medical Officer
2018
Eldon Mayer
Rigel Pharmaceuticals
Executive Vice President, Chief Commercial Officer
2018
Esteban Masuda
Rigel Pharmaceuticals